HOXA5 is a tumor suppressor gene that is decreased in gastric cancer

Peng,Xudong; Zha,Lang; Chen,Anqi; Wang,Ziwei

doi:10.3892/or.2018.6537

HOXA5 is a tumor suppressor gene that is decreased in gastric cancer

Authors:
- Xudong Peng
- Lang Zha
- Anqi Chen
- Ziwei Wang
View Affiliations

Affiliations: Gastrointestinal Surgical Unit, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400000, P.R. China
Published online on: July 2, 2018 https://doi.org/10.3892/or.2018.6537
Pages: 1317-1329
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The abnormal expression of homeobox A5 (HOXA5) has been observed in breast and colon cancer; however, the clinical significance of HOXA5 in gastric cancer (GC) is not yet clear. In this study, we found that HOXA5 expression was decreased in GC tissues at the mRNA and protein level compared with paracancerous tissues using reverse transcription‑quantitative PCR (RT‑qPCR) and western blot analysis, respectively. Immunohistochemistry and Kaplan‑Meier survival analysis confirmed that the underexpression of HOXA5 was associated with GC progression and indicated a poor prognosis of patients with GC. Given that proliferation‑related genes may be potential target genes of HOXA5, we performed a series of experiments in vitro to examine the effects of HOXA5 on the proliferation of GC cells. A CCK‑8 assay, colony formation assay and flow cytometry revealed that HOXA5 inhibited the abnormal proliferation of GC cells, and this finding was further supported by a 5‑ethynyl‑2'‑deoxyuridine (EdU) assay. Further mechanistic investigation clarified that HOXA5 promoted the protein expression of p21 and inhibited the protein expression of c‑Myc and Ki67. Additionally, the use of nude mouse models also verified that HOXA5 suppressed the proliferation of GC cells in vivo. Collectively, the findings of this study demonstrate that HOXA5 acts as a tumor suppressor gene during the development and progresion of GC, possibly functioning by inhibiting the abnormal proliferation of cancer cells.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jiang H, Shah S and Hilt DC: Organization, sequence, and expression of the murine S100 beta gene. Transcriptional regulation by cell type-specific cis-acting regulatory elements. J Biol Chem. 268:20502–20511. 1993.PubMed/NCBI
3	Boucherat O, Montaron S, Bérubé-Simard FA, Aubin J, Philippidou P, Wellik DM, Dasen JS and Jeannotte L: Partial functional redundancy between Hoxa5 and Hoxb5 paralog genes during lung morphogenesis. Am J Physiol Lung Cell Mol Physiol. 304:L817–L830. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ordóñez-Morán P, Dafflon C, Imajo M, Nishida E and Huelsken J: HOXA5 counteracts stem cell traits by inhibiting wnt signaling in colorectal cancer. Cancer Cell. 28:815–829. 2015. View Article : Google Scholar : PubMed/NCBI
5	Chen H, Zhang H, Lee J, Liang X, Wu X, Zhu T, Lo PK, Zhang X and Sukumar S: HOXA5 acts directly downstream of retinoic acid receptor beta and contributes to retinoic acid-induced apoptosis and growth inhibition. Cancer Res. 67:8007–8013. 2007. View Article : Google Scholar : PubMed/NCBI
6	Wang CC, Su KY, Chen HY, Chang SY, Shen CF, Hsieh CH, Hong QS, Chiang CC, Chang GC, Yu SL and Chen JJ: HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma. PLoS One. 10:e1241912015.
7	Loh M, Liem N, Vaithilingam A, Lim PL, Sapari NS, Elahi E, Mok ZY, Cheng CL, Yan B, Pang B, et al: DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: A comprehensive profiling approach. BMC Gastroenterol. 14:552014. View Article : Google Scholar : PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
10	Feng QY, Hu ZX, Song XL and Pan HW: Aberrant expression of genes and proteins in pterygium and their implications in the pathogenesis. Int J Ophthalmol. 10:973–981. 2017.PubMed/NCBI
11	Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM: Cancer-initiating cell markers. Curr Mol Med. 8:784–804. 2008. View Article : Google Scholar : PubMed/NCBI
12	Simon T, Gagliano T and Giamas G: Direct effects of anti-angiogenic therapies on tumor cells: VEGF signaling. Trends Mol Med. 23:282–292. 2017. View Article : Google Scholar : PubMed/NCBI
13	Chen Y, Pan K, Wang P, Cao Z, Wang W, Wang S, Hu N, Xue J, Li H, Jiang W, et al: HBP1-mediated regulation of p21 protein through the Mdm2/p53 and TCF4/EZH2 pathways and its impact on cell senescence and tumorigenesis. J Biol Chem. 291:12688–12705. 2016. View Article : Google Scholar : PubMed/NCBI
14	Gupta A, Kaur CD, Jangdey M and Saraf S: Matrix metalloproteinase enzymes and their naturally derived inhibitors: Novel targets in photocarcinoma therapy. Ageing Res Rev. 13:65–74. 2014. View Article : Google Scholar : PubMed/NCBI
15	Spitzwieser M, Pirker C, Koblmüller B, Pfeiler G, Hacker S, Berger W, Heffeter P and Cichna-Markl M: Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget. 7:73347–73369. 2016. View Article : Google Scholar : PubMed/NCBI
16	Zhang ML, Nie FQ, Sun M, Xia R, Xie M, Lu KH and Li W: HOXA5 indicates poor prognosis and suppresses cell proliferation by regulating p21 expression in non small cell lung cancer. Tumour Biol. 36:3521–3531. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ilson DH: Angiogenesis in gastric cancer: Hitting the target? Lancet. 383:4–6. 2014. View Article : Google Scholar : PubMed/NCBI
18	Mikhail S, Albanese C and Pishvaian MJ: Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers. Am J Pathol. 185:1185–1197. 2015. View Article : Google Scholar : PubMed/NCBI
19	Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, et al: Inactivation of Capicua drives cancer metastasis. Nat Genet. 49:87–96. 2017. View Article : Google Scholar : PubMed/NCBI
20	Wang B, Chen Q, Cao Y, Ma X, Yin C, Jia Y, Zang A and Fan W: LGR5 is a gastric cancer stem cell marker associated with stemness and the EMT signature genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1. PLoS One. 11:e1689042016. View Article : Google Scholar
21	Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J and Sukumar S: Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature. 405:974–978. 2000. View Article : Google Scholar : PubMed/NCBI
22	Nieto MA: Context-specific roles of EMT programmes in cancer cell dissemination. Nat Cell Biol. 19:416–418. 2017. View Article : Google Scholar : PubMed/NCBI
23	Aubin J, Déry U, Lemieux M, Chailler P and Jeannotte L: Stomach regional specification requires Hoxa5-driven mesenchymal-epithelial signaling. Development. 129:4075–4087. 2002.PubMed/NCBI
24	Teo WW, Merino VF, Cho S, Korangath P, Liang X, Wu RC, Neumann NM, Ewald AJ and Sukumar S: HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24. Oncogene. 35:5539–5551. 2016. View Article : Google Scholar : PubMed/NCBI
25	Wang Y, Xu L and Jiang L: MiR-1271 promotes non-small-cell lung cancer cell proliferation and invasion via targeting HOXA5. Biochem Biophys Res Commun. 458:714–719. 2015. View Article : Google Scholar : PubMed/NCBI
26	Yang HW, Chung M, Kudo T and Meyer T: Competing memories of mitogen and p53 signalling control cell-cycle entry. Nature. 549:404–408. 2017. View Article : Google Scholar : PubMed/NCBI
27	Ratti S, Ramazzotti G, Faenza I, Fiume R, Mongiorgi S, Billi AM, McCubrey JA, Suh PG, Manzoli L, Cocco L and Follo MY: Nuclear inositide signaling and cell cycle. Adv Biol Regul. 67:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
28	Waldman T: The inaugural use of gene editing for the study of tumor suppressor pathways in human cells-p21WAF1/CIP1. Cancer Res. 76:4598–4601. 2016. View Article : Google Scholar : PubMed/NCBI
29	LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847–862. 1997. View Article : Google Scholar : PubMed/NCBI
30	Feng F, Ren Q, Wu S, Saeed M and Sun C: Hoxa5 increases mitochondrial apoptosis by inhibiting Akt/mTORC1/S6K1 pathway in mice white adipocytes. Oncotarget. 8:95332–95345. 2017. View Article : Google Scholar : PubMed/NCBI